Asymptomatic gross hematuria followed by persistent microhematuria

Acta Paediatrica Taiwanica

Volumn 41, Issue 1, 2000, Pages 2-5

  Roth, Karl S ^a   Amaker, Barbara ^a   Chan, James C M ^a,b  

^a VIRGINIA COMMONWEALTH UNIVERSITY   (United States)

^b VIRGINIA COMMONWEALTH UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

Gross hematuria; IgA nephropathy; Thin basement membrane nephropathy

Indexed keywords

ADOLESCENT; CASE REPORT; DIFFERENTIAL DIAGNOSIS; HEMATURIA; HUMAN; IMMUNOGLOBULIN A NEPHROPATHY; KIDNEY POLYCYSTIC DISEASE; MALE; PROGNOSIS; REMISSION; REVIEW;

ADOLESCENT; BIOPSY; DIAGNOSIS, DIFFERENTIAL; GLOMERULONEPHRITIS, IGA; HEMATURIA; HUMANS; KIDNEY; MALE;

EID: 0034123446     PISSN: 00016578     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (18)

1. Wyatt RJ, Kritchevsky SB, Woodford SY, et al Long term follow-up of IgA nephropathy diagnosed in childhood. J Pediatr 1995, 27:913-5
2. D'Amico G. The commonest glomerulonephrites in the world. Q J Med 1987, 64:709-27.
3. Agodoa LYC. United States Renal Data System: Excerpts from 1995 Annual Data Report. Am J Kidney Dis 1995; 26:S69-94.
4. Hisano S, Latta K, Chan JCM. Hypercalciuria and hematuria in childhood. Kidney 1993; 2:69-72.
5. Scheinman JI, Trachtman H, Lin CY, et al IgA nephropathy: To treat or not to treat? Nephron 1997; 75 251-8
6. Falk MC, Ng G, Zhang GY, et al Infiltration of the kidney by αβ and γδ T cells: Effect on progression in IgA nephropathy. Kidney Int 1995, 47:177-85
7. Trachtman H, Chan JCM, Chan W, et al. Vitamin E ameliorates renal injury in an experimental model of immunogloublin A nephropathy. Pediatr Res 1996; 40: 620-6.
8. Nolin L, Courteau M. Management of IgA nephropathy: evidence-based recommendations. Kidney Int Suppl 1999; 70 S56-62.
9. Cattran DC, Greenwood C, Ritchie S. Long-term benefits of angiotensin-converting enzyme inhibitor therapy in patients with severe immunoglobulin a nephropathy: a comparison to patients receiving treatment with other antihypertensive agents and to patients receiving no therapy. Am J Kidney Dis 1994, 23(2):247-54.
10. Masunaga Y, Tabei K, Takeda S, et al. Effect of the angiotensin converting enzyme inhibitor, captopril, on proteinuria in chronic glomerular disease. Nippon Jinzo Gakkai Shi 1993; 35(8):961-6.
11. Praga M, Hernandez E, Montoyo C. Long-term beneficial effects of angiotensin-converting enzyme inhibition in patients with nephrotic proteinuria Am J Kidney Dis 1992, 20(3):240-8.
12. Feriozzi S, Pierucci A, Roscia, et al. Angiotensin converting enzyme inhibition delays the progression of chronic renal failure in hypertensive patients with immunoglobulin A nephropathy J Hypertens Suppl 1989; 7(7):S63-4
13. Palla R, Panichi V, Finato V, et al. Effect of increasing doses of lisinopril on proteinuria of normotensive patients with IgA nephropathy and normal renal function. Int J Clin Pharmacol Res 1994, 14(1):35-43
14. Linne T, Berg U, Bohman SO, et al. Course and long-term outcome of idiopathic IgA nephropathy in children. Pediatr Nephrol 1991; 5(4):383-6.
15. Russo D, Pisani A, Balletta MM, et al. Additive antiproteinuric effect of converting enzyme inhibitor and losartan in normotensive patients with IgA nephropathy. Am J Kidney Dis 1999; 33(5):851-6.
16. Maschio G, Cagnoli L, Claroni F. ACE inhibition reduces proteinuria in normotensive patients with IgA nephropathy: a multicentre, randomized, placebo-controlled study. Nephrol Dial Transplant 1994, 9(3):265-9
17. Perico N, Remuzzi A, Sangalli F, et al The antiproteinuric effect of angiotensin antagonism in human IgA nephropathy is potentiated by indomethacin. J Am Soc Nephrol 1998; 9(12):2308-17
18. Hogg RJ. A randomized, placebo-controlled, multicenter trial evaluating alternate-day prednisone and fish oil supplements in young patients with immunoglobulin A nephropathy. Scientific Planning Committee of the IgA Nephropathy Study. Am J Kidney Dis 1995, 26(5):792-6.